FDA Expands Novavax EUA for Use in Children 12 to 17

The Novavax COVID-19 Vaccine has received an expansion of the emergency use authorization (EUA) from the FDA. The expanded EUA allows the vaccine to be administered as a two dose primary series for children aged 12 through 17. The vaccine was previously authorized under an EUA for adults 18+. Read more about the announcement.